Skip to main content
  • Donate Blood (Opens in a new tab/window)
  • About NBA
  • News and updates
  • Resources
  • BloodPortal login (Opens in a new tab/window)
Logo image Logo image
  • Blood Products
    • Blood Products
    • National Product Price List
    • Fresh Blood Products
    • Albumin Products
    • Clotting Factor and Other Products
    • Immunoglobulin Products
      • Immunoglobulin Usage and Data
      • Intravenous Immunoglobulin (IVIg)
      • Subcutaneous Immunoglobulin (SCIg)
      • Normal Human Immunoglobulin (NHIg)
      • Hyperimmune Immunoglobulin Products
    • Access and Ordering
      • BloodSTAR for Ig Products
      • BloodSTAR Registration Form
      • BloodNet for Blood Products from Lifeblood
      • BloodNet System Interface
      • Frequently Asked Questions
    • Blood Product Management
      • Inventory Management
      • Blood Product Wastage
      • Blood and Inventory Management Resources
      • Case Studies
      • Single Unit Transfusion Guide
  • Supply System
    • Supply System
    • Managing Blood Supply
      • Risk Management
      • National Stewardship Program
      • Blood Product Labelling
    • Governance for Immunoglobulin Products
      • National Immunoglobulin Governance Committees
      • Criteria for Immunoglobulin Products
    • Suppliers and Commercial Supply Contracts
      • Fresh Blood Product Supply and Lifeblood
      • Plasma and Recombinant Product Supply
      • Imported Product Supply
      • Red Cell Diagnostic Product Supply
    • Australian Health Provider Access to Blood and Blood Products
    • Overseas Supply of Blood Products
  • Clinical Guidance
    • Clinical Guidance
      • Rh D Ig Guideline (Opens in a new tab/window)
      • PBM Guidelines (Opens in a new tab/window)
    • National Standards
    • Immunoglobulin
    • Patient Blood Management
      • Patient Blood Management (PBM) Resources
    • Transfusion-related Adverse Events
    • Bleeding Disorders
      • Australian Bleeding Disorders Registry (ABDR)
    • eLearning Courses
    • Public Consultations
    • Patient Blood Management Guidelines (Opens in a new tab/window)
  • Data and Research
    • Data and Research
    • Data and Reporting
    • Research Funding Program
      • Successful Grant Rounds
  • Patient Information
    • Patient information
    • Bleeding disorders
    • Blood disorders
    • Travelling with blood products
    • MyABDR app and the ABDR

Search

  • Donate Blood (Opens in a new tab/window)
  • About NBA
  • News and updates
  • Resources
  • BloodPortal login (Opens in a new tab/window)
  • Blood Products
    • Blood Products
    • National Product Price List
    • Fresh Blood Products
    • Albumin Products
    • Clotting Factor and Other Products
    • Immunoglobulin Products
      • Immunoglobulin Usage and Data
      • Intravenous Immunoglobulin (IVIg)
      • Subcutaneous Immunoglobulin (SCIg)
      • Normal Human Immunoglobulin (NHIg)
      • Hyperimmune Immunoglobulin Products
    • Access and Ordering
      • BloodSTAR for Ig Products
      • BloodSTAR Registration Form
      • BloodNet for Blood Products from Lifeblood
      • BloodNet System Interface
      • Frequently Asked Questions
    • Blood Product Management
      • Inventory Management
      • Blood Product Wastage
      • Blood and Inventory Management Resources
      • Case Studies
      • Single Unit Transfusion Guide
  • Supply System
    • Supply System
    • Managing Blood Supply
      • Risk Management
      • National Stewardship Program
      • Blood Product Labelling
    • Governance for Immunoglobulin Products
      • National Immunoglobulin Governance Committees
      • Criteria for Immunoglobulin Products
    • Suppliers and Commercial Supply Contracts
      • Fresh Blood Product Supply and Lifeblood
      • Plasma and Recombinant Product Supply
      • Imported Product Supply
      • Red Cell Diagnostic Product Supply
    • Australian Health Provider Access to Blood and Blood Products
    • Overseas Supply of Blood Products
  • Clinical Guidance
    • Clinical Guidance
      • Rh D Ig Guideline
      • PBM Guidelines
    • National Standards
    • Immunoglobulin
    • Patient Blood Management
      • Patient Blood Management (PBM) Resources
    • Transfusion-related Adverse Events
    • Bleeding Disorders
      • Australian Bleeding Disorders Registry (ABDR)
    • eLearning Courses
    • Public Consultations
    • Patient Blood Management Guidelines
  • Data and Research
    • Data and Research
    • Data and Reporting
    • Research Funding Program
      • Successful Grant Rounds
  • Patient Information
    • Patient information
    • Bleeding disorders
    • Blood disorders
    • Travelling with blood products
    • MyABDR app and the ABDR

Inventory management for blood and blood products

  • Home
  • Blood product management
  • Inventory management for blood and blood products

Inventory management is an essential element of blood product management. It applies to every stage of supplying and using blood and blood products, including:

  • ordering products
  • storing products
  • handling products
  • issuing products.

Managing blood and blood products

Good inventory management covers:

  • product availability – planning inventory levels held, order volume, and timing of deliveries
  • product integrity – controlling products in stock and handling them to maintain availability and minimise wastage.

Australian Health Providers (AHPs) need to manage blood and blood products effectively.

Not holding enough product could put patients at risk and disrupt routine services.

Holding too much product can increase the age of blood at transfusion and blood wastage. It can also deplete the supplier's inventory to insufficient levels.

Responsibilities

AHPs have responsibilities for effective inventory management under the:

  • National Stewardship Statement
  • Blood Management Standard.

National Stewardship Statement

Blood Management Standard

Managing Group O RhD negative red blood cells

The NBA and Australian Red Cross Lifeblood are working together to manage increasing requests for group O RhD negative red blood cells across Australia. An analysis published in the Medical Journal of Australia(Opens in a new tab/window) in 2022 found that, while only 6.5% of the Australian population is group O RhD negative, group O RhD negative red blood cells represent up to 17% of issues to AHPs.

This means AHPs were issued with group O RhD negative units at almost 3 times the Australian population distribution rate.

As a result, we have worked with health professionals to create specific guidelines for managing group O RhD negative red blood cell inventory.

National Statement for the Emergency Use of Group O Red Blood Cells

The NBA, National Blood Transfusion Committee (Australian Red Cross Lifeblood), Australian and New Zealand Society of Blood Transfusion, National Pathology Accreditation Advisory Council, Australian College of Rural and Remote Medicine and Australian College of Emergency Medicine have developed and published a joint national statement: National Statement for the Emergency Use of Group O Red Blood Cells (National Statement).

The NBA formed an expert working group consisting of representatives from key organisations, including:

  • National Blood Transfusion Committee
  • Australian and New Zealand Society of Blood Transfusion
  • National Pathology Accreditation Advisory Council
  • Australian College of Rural and Remote Medicine
  • Australian College of Emergency Medicine
  • Small and large jurisdictions – South Australia and Queensland
  • Independent experts from Queensland and New South Wales who have implemented a program in their hospital or jurisdiction.

The expert working group requested consultation on the National Statement from key professional clinical organisations and jurisdictions before finalisation.

  • National Statement for the Emergency Use of Group O Red Blood Cells
    397.66 KB

National Guidance for the Management of Red Blood Cell Inventory

  • National Guidance for the Management of Red Blood Cell Inventory
    387.21 KB

The National Guidance for the Management of Red Blood Cell Inventory (RBC Inventory Guidance) complements the National Statement.

It supports AHPs to:

  • implement the National Statement
  • reduce the national burden on group O RhD negative red blood cells.

RBC Inventory Guidance provides advice for AHPs to assist with reviewing their red blood cell inventory to:

  • reduce reliance on group O RhD negative red blood cells
  • maintain appropriate ABO and RhD blood group stock numbers that meet clinical need while maintaining an appropriate level to minimise time expiry.

National Statement for the Emergency Use of Clinical Plasma

The expert working group has also developed the National Statement for the Emergency Use of Clinical Plasma (National Plasma Statement) to address the ongoing supply strain of group AB clinical plasma.

Clinical plasma is only collected from group AB male donors at collection sites within range of a processing centre. This enables freezing the plasma within the regulated time frame (6 to 18 hours).

Using group A clinical plasma for emergency blood resuscitation is a safe option that provides clinical benefit and eases pressure on group AB donors and supplies.

Clinical plasma includes:

  • fresh frozen plasma
  • extended-life plasma
  • cryoprecipitate.

The expert working group requested consultation on the National Plasma Statement from key professional clinical organisations and jurisdictions before finalisation.

  • National Statement for the Emergency Use of Group A Clinical Plasma
    262.82 KB

Blood and Inventory Management Resources

We have developed tools and resources to improve and support blood management. The tools and resources are available to assist you with improving your blood and inventory management and meeting your responsibilities under the National Stewardship Statement and Blood Management Standard.

Blood and Inventory Management Resources | National Blood Authority

Get in touch

If you have a query about managing blood and blood product inventory, please contact us.

Last updated: 27 Mar 2024

Back to top

The National Blood Authority acknowledges the Traditional Owners and Custodians of Country throughout Australia, and their continuing connection to land, water and community. We pay our respects to the people, the cultures and the elders past, present and emerging.

National Blood Authority

  • About the NBA
  • Work with us
  • Contact Us
  • Data and reporting
  • Freedom of information
  • Public interest disclosure
  • Resources
  • Accessibility
  • Privacy
  • Copyright
  • Disclaimer
  • BloodPortal Terms and Conditions of Use

Information

  • Blood Products
  • Managing blood supply
  • Supply systems
  • Clinical guidance
  • Patient information
  • Data and research
  • Website feedback